Clinical Landscape of Littoral Cell Angioma in the Spleen Based on a Comprehensive Analysis

Weijie Wang†, Guangzhao Qi‡, Xiangtian Zhao§, Yanping Zhang¶, Rongtao Zhu†, Ruopeng Liang† and Yuling Sun∗

1 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 2 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 3 Department of Radiology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, 4 Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Objective: Littoral cell angioma (LCA) is currently considered to be a rare splenic tumor with malignant potential. As the epidemiology, pathogenesis, clinical manifestation, treatment, and prognosis remain unclear, the clinical diagnosis and treatment of LCA have not been standardized. Hence, we performed a comprehensive analysis of 189 observational studies comprising 435 patients to improve the current status of diagnosis and treatment.

Methods: PubMed, Embase, WanFang and CNKI were searched from inception to May 2021 to identify LCA studies that were published in English and Chinese. The clinical information of LCA patients were extracted and analyzed.

Results: The LCA has a male-to-female ratio of 0.90 and a solitary-to-multiple ratio of 0.31. In terms of clinical features, 69.7% of the patients showed splenomegaly, 49.7% were asymptomatic, and 39.2% experienced epigastric discomfort. As the imaging findings of patients with LCA were nonspecific, an image-guided biopsy (10/12) was a safe and effective method for diagnosing in this condition. Notably, results of the prognostic analysis indicated that LCA has a lower risk of recurrence and metastasis. The patient may develop a stable disease or the tumor will grow but will not metastasize. Besides, the novel immunohistochemical pattern of LCA was described as CD31+/ERG+/FVIII Antigen+/CD68+/CD163+/lysozyme+/CD8−/WT1−.

Conclusion: LCA should be reconsidered as a benign primary splenic vascular neoplasm, which is more like an intra-splenic manifestation of abnormal body function. Image-guided biopsy with follow-up might be a beneficial choice for LCA patients. For LCA patients with abdominal discomfort, pathological uncertainty or continuous tumor enlargement, splenectomy remains the preferred treatment.

Keywords: littoral cell angioma, diagnosis, treatment, prognosis, systematic review
INTRODUCTION

Littoral cell angioma (LCA) is a rare splenic vascular neoplasm originating from the littoral cell lining the red sinuses (1–4). Falk was the first to describe and name this entity; since its initial description, more and more studies have been conducted to investigate LCA (1, 5–9). Due to the extremely low incidence and a lack of awareness of LCA, all studies were conducted as case reports and only included less than 27 samples; moreover, nearly all the cases were misdiagnosed as other diseases (10–12). The diagnosis of LCA was primarily based on the pathological findings (1, 12, 13). In fact, littoral cell tumors (LCT) could be divided into three types with the same immunophenotype, namely, LCA, littoral cell hemangioendothelioma (LCHE), and littoral cell angiosarcoma (LCAS) (14). Because the latter two exhibited a typical nuclear atypia and malignant biological behavior, they were considered to have an intermediate malignant potential and malignant, respectively. Although LCA was considered as benign by clinicians, it was closely related to a variety of malignant tumors (14). Moreover, some patients with LCA developed recurrence and distant metastasis (11, 15, 16). Thus, LCA has always been recognized as a primary tumor of the spleen with a malignant potential.

Currently, the majority of LCA patients who underwent splenectomy were at the risk of long-term complications such as sepsis, thrombus and tumor (17, 18). As little is known about the epidemiology, natural history, pathogenesis, clinical manifestations, treatment, and prognosis of LCA, an objective evaluation of all LCA cases reported is a pressing need with important clinical significance. However, systematic and quantitative assessments of the published findings of LCA patients have not been conducted. Therefore, we aimed to perform a systematic review and analysis of all LCA cases to summarize its characteristics and to explore a new mode of diagnosis and treatment.

MATERIALS AND METHODS

Data Sources and Search Strategy

Two researchers independently searched the PubMed, Embase, WanFang, and CNKI databases from the inception to May 2021 to find published articles related to LCA. The search terms used included littoral cell angioma or littoral cell tumor or littoral cell without restrictions. Furthermore, the reference lists of the retrieved studies and recent reviews were reviewed to identify additional potentially relevant articles. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University (2017-xy-002). The typical imaging and pathological pictures presented in the figures were obtained from our center.

Data Extraction

Two investigators independently evaluated all records by screening the title and abstract for potentially eligible studies, and differences in opinion were resolved by consensus with a third reviewer. Studies (i) in which a postoperative pathology confirmed the diagnosis of LCA; (ii) that reported the epidemiology, natural history, pathogenesis, clinical manifestations, treatment and prognosis of LCA; (iii) that were published in English or Chinese before May 2021; were included in the analysis. However, reviews and LCA patients repeatedly published by the same unit were excluded. The clinical information on the epidemiology, pathogenesis, clinical manifestation, treatment, and prognosis of LCA patients were extracted and analyzed.

Statistical Analyses

The graph was drawn using Graph Pad statistics software (Graph Pad Software Inc, USA). The statistical indexes were expressed as mean and standard deviation with enumeration data, which were consistent with the normal distribution. Otherwise, it was expressed as median and interquartile range (IQR).

RESULTS

General Characteristics of the LCA Population

A total of 189 studies comprising 435 patients met the inclusion criteria (Figure 1, Table 1, and Table S1), namely, 171 foreigners and 264 Chinese individuals. The statistical analysis showed a male-to-female ratio of 0.90 in 405 patients with LCA, which indicated the absence of gender predilection. The average age of 267 patients was 48.4 ± 16 years, with the oldest and youngest being 86 years old and 26 days old, respectively (11, 19). As shown in Figure 2, LCA was more prevalent in the 40–60-year age group; however, it was detected in 15 minors (1, 19–30).

A total of 60 various malignant tumors co-occurred with LCA (1, 11, 12, 31–65), as shown in Table 1 and Figure 2, with a comorbidity rate of 13.8%. A total of 59 patients had comorbid malignancies, which occurred before the formation of LCA. Only one patient died of gastric cancer 2 years after undergoing splenectomy (53). Considering the typical survival time of gastric cancer, we speculated that this LCA patient was very likely to have developed gastric cancer at or before the time of splenectomy. Moreover, 53 immune disorders occurred along with LCA (1, 9, 11, 24, 27, 34, 35, 39, 44, 48, 50, 52, 66–88), with a comorbidity rate of 12.2%. It is worth noting that 9 patients had both malignant tumors and immune dysfunctions prior to the development of LCA. In addition, we summarized the different benign comorbidities reported for reference by other studies (Figure 2).

Quantification and Analysis of the Clinical Manifestations and Prognosis

A total of 314 patients were described with symptoms, of whom 49.7% were asymptomatic or accidental findings, 39.2% experienced upper abdominal discomfort, and 5.4% developed fever, as shown in Table 2. The spleen size was measured in 366 LCA patients, and 69.7% of them showed splenomegaly. Approximately 48.8% (127/260) of the patients had...
thrombocytopenia, while 31.4% (69/220) had anemia. Given its malignant potential, splenectomy with long-term follow up is the recommended treatment for LCA. Of the 401 patients, 81.0 and 19.0% underwent open and laparoscopic splenectomy, respectively. Although the accurate diagnosis rate was only 83.3% (12), image-guided biopsy was a relatively safe method when spleen lesions were difficult to diagnose.

Furthermore, 174 patients had a clear prognosis (Table 2). A total of 159 (91.4%) patients survived without recurrence or metastasis after undergoing splenectomy. However, three patients developed recurrence or metastasis (11, 15, 16). In fact, one patient developed tumor recurrence in the accessory spleen 7 years after undergoing splenectomy, which showed no significant change during the 6-month follow-up (16). According to our statistics, four patients developed LCA both in the spleen and accessory spleen (16, 43, 89, 90). Therefore, it was quite reasonable to find a recurrence of LCA on the unresected accessory spleen. Strictly speaking, this should not be considered as a true relapse or metastasis, and we would rather think that a new LCA has formed in the accessory spleen. In the second patient, the co-occurrence of LCA along with LCHE was detected during splenectomy 8 years ago; the patient unfortunately died of abdominal multiple recurrence and metastasis (11). However, we think that it was the LCHE and not the LCA that recurred and metastasized. Actually, only the third case could be narrowly regarded as recurrence and metastasis, which presented as hepatomegaly with multiple metastatic tumors after splenectomy 10 years and was confirmed by open liver biopsy (15). Even so, the possibility of atypical LCHE or LCAS could not be ruled out.

Sixteen patients died during the follow-up period (1, 11, 12, 15, 39, 53, 58, 59, 91, 92). Among them, eight patients died from...
concurrent primary malignancies, namely, 2 gastric cancers, 2 malignant lymphomas, 1 multiple myeloma, 1 colon cancer, 1 pancreatic cancer, and 1 ovarian cancer. Four died of postoperative complications. Two patients died at 1.5 and 6 years, respectively, after splenectomy due to unknown causes. The other two patients who died were due to the recurrence and metastasis of the tumor to the liver. In fact, one of them died due to the recurrence and metastasis of LCHE (11), while the other died of hemorrhagic cerebral infarction 21 months after the diagnosis of intrahepatic metastatic LCA (15). Obviously, these causes of death had no direct correlation with LCA.

**Imaging Features of the LCA Patients**

First, the ultrasound (US) features of 92 LCA patients are summarized in Table 3. LCA manifested as hyperechoic (Figure 3A), hypoechoic, isoechoic, and heterogeneous echo in 43.5, 35.9, 9.8, and 10.9% of the patients, respectively. On the color Doppler imaging of 25 LCA patients, the color flow signals were 76% of hypovascular and 24% of hypervascular. There were relatively few data on the contrast-enhanced ultrasound (CEUS) findings. All 8 LCA patients who underwent CEUS showed enhancement in arterial phase. Of the 7 patients with portal phase description, 6 patients had enhanced features in CEUS. Only 3 patients had a description of delayed phase, and 2 patients presented enhancement. Second, 214 LCA patients underwent concurrent primary malignancies, namely, 2 gastric cancers, 2 malignant lymphomas, 1 multiple myeloma, 1 colon cancer, 1 pancreatic cancer, and 1 ovarian cancer. Four died of postoperative complications. Two patients died at 1.5 and 6 years, respectively, after splenectomy due to unknown causes. The other two patients who died were due to the recurrence and metastasis of the tumor to the liver. In fact, one of them died due to the recurrence and metastasis of LCHE (11), while the other died of hemorrhagic cerebral infarction 21 months after the diagnosis of intrahepatic metastatic LCA (15). Obviously, these causes of death had no direct correlation with LCA.

**Imaging Features of the LCA Patients**

First, the ultrasound (US) features of 92 LCA patients are summarized in Table 3. LCA manifested as hyperechoic (Figure 3A), hypoechoic, isoechoic, and heterogeneous echo in 43.5, 35.9, 9.8, and 10.9% of the patients, respectively. On the color Doppler imaging of 25 LCA patients, the color flow signals were 76% of hypovascular and 24% of hypervascular. There were relatively few data on the contrast-enhanced ultrasound (CEUS) findings. All 8 LCA patients who underwent CEUS showed enhancement in arterial phase. Of the 7 patients with portal phase description, 6 patients had enhanced features in CEUS. Only 3 patients had a description of delayed phase, and 2 patients presented enhancement. Second, 214 LCA patients underwent concurrent primary malignancies, namely, 2 gastric cancers, 2 malignant lymphomas, 1 multiple myeloma, 1 colon cancer, 1 pancreatic cancer, and 1 ovarian cancer. Four died of postoperative complications. Two patients died at 1.5 and 6 years, respectively, after splenectomy due to unknown causes. The other two patients who died were due to the recurrence and metastasis of the tumor to the liver. In fact, one of them died due to the recurrence and metastasis of LCHE (11), while the other died of hemorrhagic cerebral infarction 21 months after the diagnosis of intrahepatic metastatic LCA (15). Obviously, these causes of death had no direct correlation with LCA.
In intensity (T2WI), the splenic lesions mostly manifested as a high signal intensity, respectively. On unenhanced T2-weighted images and T1-weighted images (T1WI), the lesions were depicted as.

Features of 66 LCA patients were summarized. On unenhanced imaging, and 62.8% presented enhancement. Of the 45 LCA patients with arterial phase imaging, 94.8% characterized by delayed enhancement.

In 30 patients with delayed phase imaging, 93.3% showed enhancement. Of the 30 patients with delayed phase imaging, 93.3% characterized by delayed enhancement (Figures 3H, I).

In nine patients who underwent positron emission tomography/CT examination, 7 who developed the splenic lesions had no abnormal uptake (11, 32, 33, 35, 36, 65, 93) (Figure 3C). However, 2 patients showed high uptake of 18F-fluorodeoxyglucose (11, 94). The other 10 patients underwent single-photon emission computed tomography, of whom 6 showed 99 mTc uptake (76, 80, 95–98), 2 showed Ga uptake (47, 89), and 2 had undescribed radionuclides (28, 99). Based on these results, only 30% of the patients showed a high uptake.

Characteristics of Spleen and LCA

The size and weight of the spleen slightly to moderately increased (Table 4). In the splenomegaly group, the median splenic volume and weight were 1,140 cm³ and 575 g, with the maximum volume and weight being 5,040 cm³ and 4,018 g, respectively. Meanwhile, the median splenic volume and weight were only 389 cm³ and 187 g, respectively, in the normal-sized spleens. Furthermore, LCA could appear as multifocal lesions or a solitary nodule with a solitary-to-multiple ratio of 0.31 in 349 patients. The average diameter of solitary LCA was 6.4 ± 4.0 cm, with the maximum diameter being 21 cm (31). The average diameter of solitary LCA was only 3.3 ± 2.6 cm in the multiple LCA group, with the maximum diameter being 18 cm (1).

A total of 18 patients described the natural history of LCA. Detailed description of the period of LCA formation was provided for ten patients (19, 26, 38, 42, 45, 65, 70, 76, 100, 101). The median time for LCA formation was 15 m, with the shortest and longest being 26 d and 4 y, respectively. Eleven patients with untreated LCA survived during follow-up, which had no obvious symptoms of discomfort (16, 19, 43, 65, 71, 102–107). The median of follow-up time of patients with untreated LCA was 24 m, with the shortest and longest being 0.5 m and 9 y. Although significant enlargement of untreated LCA was observed in three patients, no metastasis occurred. Among them (105–107), two patients developed an increase of the tumor size in the second year, from 0.5 to 3.4 cm and 4.3 cm respectively, and one showed an increase in the tumor size of 9 cm in the ninth year.

Summary of Histopathology and Immunohistochemical Characteristics of LCA

Histologically, LCA showed sinus like anastomosing channels with an irregular lumen (Figure 4). These channels were either papillary or cystic and lined with tall, plump endothelial cells (1, 3). These endothelial cells exhibited hemophagocytosis and lacked features of nuclear atypia or mitotic activity, which was an important basis to distinguish them from other malignant tumor cells. The electron microscopic examination of LCA showed polygonal tumor cells surrounded by blood vessels (108). Notably, the vessels were only made up of a lining of medium electron density homogenous basal membrane, which lacked smooth muscles. The tumor cells of LCA had an abundant

| TABLE 3 | Imaging features of the LCA patients. |
|----------------------------------------|--------------------------------------|
| Imaging features                      | Value      | N. With data reported |
| Ultrasound imaging                   |            |                        |
| Hyperechoic                           | 43.5%      | 40/92                  |
| Hypoechoic                           | 36.9%      | 33/92                  |
| Isoechoic                             | 9.8%       | 9/92                   |
| Heterogeneous echo                   | 10.9%      | 10/92                  |
| Hypovascular                         | 76%        | 19/25                  |
| Hypervascular                        | 24%        | 6/25                   |
| Enhancement in arterial phase of CEUS* | 100%       | 8                      |
| Enhancement in portal venous phase of CEUS | 85.7%    | 6/7                    |
| Enhancement in delayed phase of CEUS  | 66.7%      | 2/3                    |
| Computed tomography imaging         |            |                        |
| Hypodense in CT scan                 | 84.5%      | 158/187                |
| Isodense in CT scan                  | 13.9%      | 26/187                 |
| Hyperdense in CT scan                | 1.6%       | 3/187                  |
| Enhancement in arterial phase        | 58.4%      | 73/125                 |
| Enhancement in portal venous phase   | 77.1%      | 118/155                |
| Enhancement in delayed phase         | 94.8%      | 91/96                  |
| Magnetic resonance imaging          |            |                        |
| T1 hyperintense                      | 6.9%       | 4/88                   |
| T1 hypointense                       | 75.9%      | 44/58                  |
| T1 isointensity                      | 17.2%      | 10/58                  |
| T2 hyperintense                      | 76.6%      | 49/64                  |
| T2 hypointense                       | 18.8%      | 12/64                  |
| T2 isointensity                      | 3.1%       | 2/64                   |
| T2 mixed signal intensity            | 1.6%       | 1/64                   |
| DWI hyperintense                     | 90%        | 27/30                  |
| DWI hypointense                      | 10%        | 3/30                   |
| Enhancement in arterial phase        | 62.8%      | 27/43                  |
| Enhancement in portal venous phase   | 88.9%      | 40/45                  |
| Enhancement in delayed phase         | 93.3%      | 28/30                  |
| PET/CT and SPECT imaging            |            |                        |
| FDG uptake                           | 22.2%      | 2/9                    |
| No abnormal FDG uptake               | 77.8%      | 7/9                    |
| High uptake of radionuclides         | 30%        | 3/10                   |
| No abnormal radionuclides uptake     | 70%        | 7/10                   |

*CEUS, Contrast-enhance Ultrasound. Bold letters represent different types of imaging examination and are a summary of the total number of published cases with imaging findings.
cytoplasm, namely, mitochondria, a rough endoplasmic reticulum, and lysosomes. Some of them showed intermediate filaments and lipofuscin bodies.

The immunohistochemical staining for littoral cells usually reveals a dual differentiation pattern for both endothelial and histiocytic markers (109) (Figure 4, Table 5). Of the histiocytic markers, CD163, CD68, lysozyme, CD4, and CD11c showed very similar staining pattern with positivity rates of 100, 99.7, 99.1, 94.7, and 87.5%, respectively. However, factor XIIIa did not react in any cells. Of the vascular markers, all of them reacted

---

**TABLE 4 | Characteristics of spleen and LCA.**

| Characteristics                                      | Value                     | N. With data reported |
|-------------------------------------------------------|---------------------------|-----------------------|
| Splenomegaly/Normal                                   | 2.3                       | 255/111               |
| Volume of splenomegaly (range, median, IQR)           | 203–5,040 cm³, 1,140 cm³, 1,119 cm³ | 75/105               |
| Volume of normal spleen (range, median, IQR)          | 98–840 cm³, 389 cm³, 239 cm³ | 30/105               |
| Weight of splenomegaly (range, median, IQR)           | 200–4,018 g, 575 g, 590 g | 71/93                |
| Weight of normal spleen (range, median, IQR)          | 120–300 g, 187 g, 64 g    | 22/93                |
| Solitary/Multiple                                    | 0.31                      | 83/266                |
| The diameter of solitary LCA (range, mean, SD)        | 0.2–21 cm, 6.4 cm, 4 cm   | 66*                  |
| The diameter of multiple LCA (range, mean, SD)        | 0.2–18 cm, 3.3 cm, 2.5 cm | 142*                 |
| Period for LCA formation (range, median, IQR)         | 0.87–48 m, 15 (14.3) m    | 10*                  |
| Follow-up period with untreated LCA (range, median, IQR)| 0.5–108 m, 24 (56.5) m  | 11*                  |

*The maximum tumor diameter.

*Detailed description of the period of LCA formation.

*Follow-up period of untreated LCA.

---
positively with CD31, BMA120, UEA-1, FLI1, LYVE1, VEGFR2, claudin-5, and LMO2. A very similar staining pattern was observed with factor VIII and ERG, with positivity rates of 98.4 and 97.2%, respectively. As a tumor suppressor gene, Wilms tumor-1 (WT-1) was involved in development of tissues from the inner layer of intermediate mesoderm and played a role in regulating angiogenesis and proliferation of vascular smooth muscle cells (110). However, all 33 LCA patients showed no reactivity with Wilms tumor-1 (WT-1) (11, 12). Only 54.3% in the 232 LCA patients stained positively for CD34.

TABLE 5 | Summary of immunohistochemical characteristics of LCA.

| Designation | Specificity | Value   | N. With data reported |
|-------------|-------------|---------|-----------------------|
| CD163       | Histiocytes | 100%    | 63/63                 |
| CD68        | Histiocytes | 99.7%   | 302/303               |
| Lysozyme    | Macrophages/Histiocytes, etc. | 99.1% | 113/114   |
| CD4         | Monocyte/macrophage cells/T lymphocyte | 94.7% | 18/19         |
| CD11c       | Dendritic cells/macrophages, etc. | 87.5% | 14/16         |
| Factor XIII | Macrophages/Histiocytes | 0% | 0/17         |
| CD31        | Endothelial cells | 100% | 276/276 |
| BMA120      | Endothelial cells | 100% | 18/18 |
| UEA-1       | Lectin: endothelial cells | 100% | 17/17 |
| FLI1        | Endothelial cells, etc. | 100% | 17/17 |
| LYVE1       | Sinusoidal endothelium, etc. | 100% | 13/13 |
| VEGFR2      | Endothelial cells, etc. | 100% | 17/17 |
| Claudin-5   | Endothelial cells | 100% | 17/17 |
| LMO2        | Endothelial cells | 98.4% | 239/243 |
| Factor VIII | Endothelial cells | 97.2% | 35/36 |
| CD34        | Endothelial cells | 54.3% | 127/234 |
| WT1         | A tumor suppressor gene | 0% | 0/33 |

| Other indicators with identification |
|--------------------------------------|
| CD8 | T lymphocytes | 11.7% | 11/94 |
| CD21 | Dendritic cells | 57.1% | 40/70 |
| S100 | Neural structures | 38.8% | 19/49 |
| D2-40 | Lymphatic endothelial cells/mesothelial cells | 0% | 0/24 |
| OK | Epithelium | 0% | 0/37 |
| EMA | Epithelium | 7.1% | 1/14 |
| Vim | Intermediate filament | 65.3% | 47/72 |
| Ki67 (range, median, IQR) | Proliferative antigen | 80.6% (0–23%, 3%, 4.1%) | 50/62* |

*Fifty patients described the positivity rates of ki67, with the highest 23% and the median 3%. Twelve patients reacted positive with ki67, but positivity rates were not described.

FIGURE 4 | The typical pathological features of LCA. (A) (×40) & (B) (×200). HE staining of LCA showed sinus-like anastomosing channels with an irregular lumen, which was lined with tall, plump endothelial cells. Of the vascular markers, LCA reacted positively with (C) CD31, (D) factor VIII, and (E) CD34. Of the histiocytic markers, LCA typically expressed with (F) CD68 and (G) CD163. (H) A positivity rates of KI67 was approximately 5%.
CD8 is typically associated with cytotoxic T cells. Its expression by littoral cells highlights the architectural framework of the red pulp in a dendritic pattern (109). Approximately 11.7% of 93 LCA patients stained positively for CD8 (108, 111). Moreover, 57.1% in the 69 patients stained positively for CD21, which is a type I transmembrane protein found on B cells, follicular dendritic cells, pharyngeal and cervical epithelial cells. In addition, S100 is a specific protein used as a marker of neurogenic tumors in pathological diagnosis. In 19 of 49 patients, the tumor cells of LCA exhibited positivity for S100 protein.

Of the lymphatic endothelial markers, D2-40 showed no reactivity in the cells of LCA (108). Similar staining pattern was also observed with epithelium marker CK. Only one of the 14 patients exhibited positivity for epithelium marker EMA (29). As a marker of mesenchymal tissue, the expression of vim indicates that the tissue originates from the mesenchymal rather than the epithelium. Approximately 65.3% of 72 LCA patients stained positively for vim. Notably, 50 patients stained positively for Ki67 with a median rate of 3%, with the minimum and maximum being 0 (112) and 23% (35), respectively. Finally, we proposed a new immunohistochemical phenotype summarized as CD31+/ERG+/FVIII antigen+/CD68+/CD163+/lysozyme+/CD8+/WT1+ to enhance the differentiation from other primary or secondary splenic tumors.

A New Mode of Diagnosis and Treatment for LCA

Based on the objective evidence, we herein proposed a process of diagnosis and treatment for LCA (Figure 5). For primary splenic space occupying lesions, non-invasive clinical examinations should be performed initially. If the lesion is considered benign, a regular follow-up for 3 to 6 months is recommended. If the nature of the tumor could not be determined or the possibility of metastasis could not be ruled out due to a history of malignant tumor, an image-guided biopsy is suggested. Then, if the tumor is confirmed as LCA without other indications for splenectomy, regular follow-up is still necessary. If it is considered as a malignant lesion, an image-guided biopsy or a direct splenectomy should be performed. In addition, for splenic tumor patients with abdominal discomfort, pathological uncertainty, or continuous tumor enlargement, splenectomy is the preferred treatment. Basically, in order to improve the diagnosis and treatment of this rare disease, regular follow-up is recommended for all patients with definite LCA.

DISCUSSION

To the best of our knowledge, this was the first systematic review and analysis of all observational studies to describe the clinical landscape of LCA. Due to the low incidence of LCA, studies on LCA published in English and Chinese were collected to summarize the epidemiological characteristics. A total of 435 participants were diagnosed with LCA with a male-to-female ratio of 0.90 (192/213), indicating no gender predilection. The age of LCA onset showed a normal distribution with the oldest and youngest being 86 y (11) and 26 d (19), respectively. Although most of the patients were aged 40–60 years, the incidence of LCA in children was not uncommon (5.7%) (1, 19–30). With regard to the natural history of LCA, 11 patients had an untreated LCA. Among them, LCA was significantly enlarged in three patients but metastasis did not occur. Besides, four patients had a relatively unusual case. One patient had chronic renal failure and underwent dialysis for 1 year, while the other three had malignant tumors. However, no significant changes were observed in the LCA during the follow-up period. Moreover, the natural formation of LCA was documented in 10 patients, with the shortest period being 26 days and the longest period being 4 years. Of the ten patients, four had a previous malignancy, while three had a coexisting immune dysfunction. Therefore, LCA was more like an intra-splenic manifestation of abnormal body function, which could remain stable for a long time or gradually grow in size.

Actually, the etiology and pathogenesis of LCA remains unknown. The available evidences suggested that it was closely related to the occurrence of malignancies (14, 43). The most common malignancies included epithelial, mesenchymal, and hematological malignancies, such as lymphoma, colorectal adenocarcinoma, pancreatic carcinoma, renal adenocarcinoma, malignant melanoma, gastric leiomyosarcoma, and non-small cell carcinoma of the lungs. In a retrospective case study by Peckova, up to 60% of the cases were found to correlate with various visceral malignancies (11). On the contrary, the study by Falk showed an entirely different result, with only 2 of the 17 cases of LCA were associated with malignancy (12%) (1). Based on the results of the systematic analysis, we obtained a similar conclusion and a comorbidity rate of 13.8% (60/435).

In addition, a number of LCA patients showed an association with diseases with presumed immune origin or systemic disease known to cause immune disturbances such as idiopathic thrombocytopenia, ulcerous colitis, Crohn’s disease, autoimmune thrombocytopenia (Evans’s syndrome), Gaucher disease, Epstein syndrome, lymphocytic colitis, myelodysplastic syndrome, chronic granulonephritis, aplastic anemia, pulmonary sarcoidosis, post-renal transplantation, hepatitis B and C, psoriasis, chemotherapy, cystostatic treatment, systemic lupus erythematosus, and so on (11, 14). Some studies also speculated that infection and splenic hemodynamic disorder might be related to the formation of LCA (3, 12, 32, 68, 95). Our statistical results showed that a total of 54 LCA patients developed diseases that could lead to immune dysfunction with a comorbidity rate of 12.2% (54/435). Nine of these patients developed both malignant tumors and immune dysfunctions prior to the formation of LCA. It should be emphasized that almost all the malignancies occurred prior to the formation of LCA, and also those immune disorders, indicating that LCA was most likely a response to an internal dysfunction, rather than an initial cause of a body disorder. In summary, immune dysregulation caused by congenital or acquired malignancies, drugs, etc., probably played a vital role in the pathogenesis of LCA.

In terms of clinical characteristics, there is no existing unified and accurate reference index for the diagnosis and treatment of
LCA. According to our statistics, patients with LCA were usually asymptomatic (49.7%) or presented with epigastric discomfort (39.2%). Most patients developed splenomegaly (69.7%). About half of them had thrombocytopenia (48.8%), and one-third of them presented with varying degrees of anemia (31.4%). Many scholars were even confused with the morphological features of LCA (82, 113). Most of them only knew that LCA often manifested as multiple lesions. In fact, solitary LCA was not uncommon with a solitary-to-multiple ratio of 0.31 (83/266). In terms of size, LCA ranged from small foci that are unremarkable in the splenic parenchyma to large lesions that are almost completely replacing the splenic parenchyma, with a known

FIGURE 5 | A process of diagnosis and treatment for LCA.
maximum diameter of 21 cm (31). Furthermore, a novel panel of immunohistochemical staining for LCA was recommended as CD31+/ERG+/FVIII antigen+/CD68+/CD163+/lysozyme+/CD8+/WT1− by summing up the previous pathological findings, which would help distinguish from other primary or secondary splenic tumors.

Imaging findings of LCA correlated well with the gross pathological features. However, US, CT, MRI, or radionuclide imaging did not provide specific findings. They could appear as diverse echoes on ultrasound, and also different densities and signals on CT and MRI with a delayed enhancement generally. Increased ADC values and delayed contrast enhancement on dynamic enhanced T1WI within the LCA lesions suggested a vascular etiology and narrowed the differential diagnosis of multifocal splenic lesions (25, 101). Occasionally, low signal areas were seen on both T1WI and T2WI within the LCA tumors, and remained hypointense after injection of gadolinium (26), which could be due to the significant amounts of hemosiderin in the lesions that caused the formation of a magnetic susceptibility artifact. Notably, most LCA lesions had no abnormal uptake of radionuclide. The overall imaging findings of LCA were consistent with the characteristics of a benign disease.

Finally, the prognosis of LCA has always been the focus of controversy (1, 15, 16, 114). Almost all scholars reported the malignant potential of LCA and the possibility of recurrence, metastasis, or developing malignant tumors. Contrary to the past view, the major findings of this study supported LCA is a benign primary splenic vascular neoplasm without the risk of recurrence or metastasis, which might be a response to an internal dysfunction, rather than an initial cause of other malignancies. According to our statistics, 91.4% (159/174) of the patients survived after undergoing splenectomy without developing adverse events. Meanwhile, 9.2% (16/174) of the patients died during the follow-up period. However, when the causes of death were analyzed, almost all of them were not related to LCA itself. Although three patients experienced recurrence or metastasis, only one could be narrowly regarded as having a real recurrence or metastasis, and the possibility of atypical LCHE or LCAS could not be ruled out. In fact, a similar metastasizing splenic LCHE has been reported by Fernandez, which showed a typical morphology and immune-phenotypes of LCA with a completely bland histological appearance (114). Based on the summary of imaging and pathological characteristics, LCA was more in line with a benign lesion. Postoperative intrahepatic or distant organ metastasis of LCA should be considered as an atypical LCHE or LCAS. Thus, none of the patients with real LCA developed recurrence or metastasis.

However, several limitations should be acknowledged. First, LCA is a rare disease that has originated in the spleen. All published studies had small sample size (<27 patients) (10). The quality of these studies was generally low. Therefore, the recommendations were mainly based on the results of observational studies. Second, the search strategy only included studies indexed in PubMed, Embase, WanFang, and CNKI, published between January 1991 and May 2021 and written in English or Chinese. Third, although a low rate of metastasis was concluded based on the results of observational studies on LCA, we were unable to assess the contribution of splenectomy to this incidence.

In conclusion, this study suggested that LCA was a benign primary splenic vascular neoplasm, which was more like an intra-splenic manifestation of abnormal body function. Accumulated evidence indicated that if LCA could be diagnosed preoperatively, further splenectomy might not be necessary, as it can increase the risk of postoperative complications and is associated with a huge economic cost; only a close follow-up is necessary. For LCA patients with abdominal discomfort, pathological uncertainty or continuous tumor enlargement, splenectomy remains the preferred treatment.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS
WW and YS designed the study. WW, RZ, and RL collected clinical data. WW, GQ, XZ, and YZ wrote the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING
The study was supported by the National Natural Science Foundation of China (81900558) and the Henan Medical Science and Technique Foundation (SBGJ202003035).

ACKNOWLEDGMENTS
The authors would like to thank Ruixia Yuan, Ruishan Wang, and Lu Wan for their professional guidance on data analysis, ultrasound and CT. The authors also thank Editage (www.editage.com) for English language editing.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.790332/full#supplementary-material

Supplementary Data Sheet 1 | All the included literatures published in English or Chinese before May 2021.
REFERENCES

1. Falk S, Stutte HJ, Frizzera G. Littoral Cell Angioma. A Novel Splenic Vascular Lesion Demonstrating Histiocytic Differentiation. Am J Surg Pathol (1991) 15(11):1023–33. doi: 10.1097/00000478-199111000-00001

2. Tsang WY, Chan JK. Splenic Littoral Cell Angioma, Not Bacillary Angiomatosis. Pathology (1994) 26(3):347. doi: 10.1080/0305625940169931

3. Bi C, Jiang L, Li Z, Liu W. Littoral Cell Angioma of Spleen: A Clinicopathologic Study of 17 Cases. Zhonghua Bing Li Xue Za Zhi (2007) 4(36):239–43. doi: 10.3760/j.issn.0529-5807.2007.04.006

4. Kaza RK, Azar S, Al-Hawary MM, Francis IR. Primary and Secondary Neoplasms of the Spleen. Cancer Imaging (2010) 10(1):173–82. doi: 10.1102/12075.2010.006440

5. Boldan-Vasquez E, Boldan-Vasquez A, Jarrin-Estupinan X, Boldan-Crespo M. A Case Report: Infrquent Littoral Cell Angioma of the Spleen. Int J Surg Case Rep (2021) 85:106242. doi: 10.1016/j.ijscr.2021.106242

6. Dascalescu CM, Wendum D, Gorin NC. Littoral-Cell Angioma as a Cause of Spleenomegaly. N Engl J Med (2001) 345(10):772–3. doi: 10.1056/NEJM200109063451016

7. Levy AD, Abbott RM, Abbondanzo SL. Littoral Cell Angioma of the Spleen: A Case Report. Blood (2017) 129(11):1564. doi: 10.1182/blood-2016-10-748772.PMID:28302694

8. Cai Y-Q, Wang X, Ran X, Liu X-B, Peng B. Laparoscopic Splenectomy for Splenic Littoral Cell Angioma. World J Gastroenterol (2015) 21(21):6660–4. doi: 10.3745/wjg.v21.i21.6660

9. Peckova K, Michal M, Hadravsky L, Suster S, Damjanov I, Miesbauerova M, et al. Littoral Cell Angioma of the Spleen: A Study of 25 Cases With Histopathological Comparison of Frequent Association With Viral Malignancies. Histopathology (2016) 69(5):762–74. doi: 10.1111/his.13026

10. Cao Z, Wei J, Cen H, Yuan X, Zhou G, Zhao J, et al. 13 Cases of Littoral Cell Angioma in Spleens. Beijing Da Xue Xue Bao Yi Xue Ban (2017) 49:495–500. doi: 10.3969/j.issn.1671-167X.2017.03.020

11. Fabiola I Sanguinorgio V, Arber DA. Vascular Neoplasms and Non-Neoplastic Vascular Lesions of the Spleen. Semin Diagn Pathol (2021) 38(2):154–8. doi: 10.1053/j.semdp.2020.07.001

12. Sarandria JJ, Escano M, Kamangar S, Faraooqi S, Montgomery E, Cunningham SC. Massive Splenomegaly Correlates With Malignancy: 180 Cases of Splenic Littoral Cell Tumors in the World Literature. Minerva Chir (2014) 69(12):229–37.

13. Takayoshi K, Doi G, Tsuruta N, Yoshihiro T, Nio K, Tsuchihashi K, et al. A Case of Littoral Cell Angioma of the Spleen Associated With Plasmablastic B-Cell Lymphoma. J Clin Oncol (2019) 21(25):576–7. doi: 10.1002/jco.28097

14. Anbardar MH, Kumar PV, Forootan HR. Littoral Cell Angioma of the Spleen: Cytological Findings and Review of the Literature. J Cytol (2017) 34(2):121–4. doi: 10.4103/JOC.JOC_118_15

15. Wang C, Tian Y, Cai W, Li N. Littoral Cell Angioma Complicating a Case of Rolon Cancer: A Case Report. Gulf J Oncol (2015) 1(19):1–4.

16. Marzetti A, Messina F, Prando D, Verza LA, Azabdaftari A, et al. Laparoscopic Splenectomy for a Littoral Cell Angioma of the Spleen: Case Report. World J Clin Cases (2015) 3(11):951–5. doi: 10.12998/wjcc.v3.i11.951

17. Marzetti A, Messina F, Prando D, Verza LA, Azabdaftari A, et al. Laparoscopic Splenectomy for Littoral Cell Angioma of the Spleen: A Case Report. World J Clin Cases (2015) 3(11):951–5. doi: 10.12998/wjcc.v3.i11.951

18. Marzetti A, Messina F, Prando D, Verza LA, Azabdaftari A, et al. Littoral Cell Angioma Complicating a Case of Rolon Cancer: A Case Report. Gulf J Oncol (2015) 1(19):1–4.

19. Marzetti A, Messina F, Prando D, Verza LA, Azabdaftari A, et al. Littoral Cell Angioma Complicating a Case of Rolon Cancer: A Case Report. Gulf J Oncol (2015) 1(19):1–4.

20. Marzetti A, Messina F, Prando D, Verza LA, Azabdaftari A, et al. Littoral Cell Angioma Complicating a Case of Rolon Cancer: A Case Report. Gulf J Oncol (2015) 1(19):1–4.

21. Marzetti A, Messina F, Prando D, Verza LA, Azabdaftari A, et al. Littoral Cell Angioma Complicating a Case of Rolon Cancer: A Case Report. Gulf J Oncol (2015) 1(19):1–4.

22. Marzetti A, Messina F, Prando D, Verza LA, Azabdaftari A, et al. Littoral Cell Angioma Complicating a Case of Rolon Cancer: A Case Report. Gulf J Oncol (2015) 1(19):1–4.
Wang et al. Splenic Littoral Cell Angioma

58. Chen J. Splenic Littoral Cell Angioma: A Clinicopathologic Analysis of

54. Liu H, Liu M, Liu Y, Xiao W, Xu S. Imaging Features of Splenic Littoral Cell

56. Huang G, Wang J, Liu B, Wang H, Yu Y. MSCT Imaging Features of the

53. Dong W, Li F, Kang Q, Li Y, Chen Y, Ma J, et al. Diagnosis and Treatment of

52. Lin C-H, Yu J-C, Shih M-L, Peng Y-J, Hsieh C-B. Littoral Cell Angioma of

51. Mokhtari N, Hamidian Jahromi A, Dela Cruz N, Woodward A, Do D,

46. Bisceglia M, Sickel JZ, Giangaspero F, Gomes V, Amini M, Michal M.

48. Selove W, Picarsic J, Swerdlow SH. Langerin Staining Identi

65. Opatrny V, Treska V, Waloschek T, Molacek J. Littoral Cell Angioma of the

8. doi: 10.1002/jcu.10101

45. Steensma DP, Morice WG. Littoral Cell Angioma Associated With Portal

44. Heese J, Bocklage T. Specimen Fine-Needle Aspiration Cytology of Littoral

41. Thomas-Ogunniyi JO, et al. Littoral Cell Angioma: Review of the Literature

39. doi: 10.3969/j.issn.1674-4136.2011.06.001

36. Tholouli E, Roulson J-A, Byers R, Burton I, Liu Yin JA. Littoral Cell

33. doi: 10.3969/j.issn.1005-7143.2011.01.026

30. Li M-J, Zhou X, Cao J-Y, Zhu C-Z, Zhou S-S, Zang Y-J, et al. Laparoscopic

28. Li G, Le M, Gao H. Clinicopathologic Features of Littoral Cell Angioma in

27. Li G, Le M, Gao H. Clinicopathologic Features of Littoral Cell Angioma in a Patient With Severe Aplastic Anaemia. Hematologica (2003) 88(9):ECR30.

26. Johnson J, Björnsson B, Ignatova S, Sandström P, Ekstedt M. Littoral Cell Angioma in a Patient With Crohn’s Disease. Case Rep Gastrointest Med (2015) 2015:474969. doi: 10.1155/2015/474969

25. Nagarajan P, Cai G, Padda MS, Selbst M, Kowalski D, Proctor DD, et al. Littoral Cell Angioma of the Spleen Diagnosed by Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy. Diagn Cytopathol (2011) 39(5):318–

24. Cordesmeyer S, Pützler M, Titze U, Paulus H, Hofmann MW. Littoral Cell Angioma of the Spleen in a Patient With Previous Pulmonary Sarcoidosis: A TNF-Alpha Related Pathogenesis? World J Surg Oncol (2011) 9:106. doi: 10.1186/1477-7819-9-106

23. Bierenbaum J, Alapat DV, Godinez C, Park AE, Frank Zhao X, Baer MR. Littoral Cell Angioma: A Correctable Cause of Progressive Pancytopenia in a Patient With Myelodysplastic Syndrome. Leuk Res (2010) 34(4):e117–

22. doi: 10.1002/djcr.21384

21. Blansfield JA, Goldhann RT Jr, Josloff RK. Littoral Cell Angioma of the Spleen Treated by Laparoscopic Splenectomy. JSLS (2005) 9(2):222–4.

20. Kim H-G, Park I-S, Lee J-L, Jeong S, Lee J-W, Kwon K-S, et al. Littoral Cell Angioma (LCA) Associated With Liver Cirrhosis. Yonsei Med J (2006) 47(3):119–26. doi: 10.3349/ymj.2006.47.3.119

19. Gupta MK, Levin M, Aguileras NS, Pastores GM. Littoral Cell Angioma of the Spleen in a Patient With Gaucher Disease. Am J Hematol (2001) 68(1):61–2. doi: 10.1002/ajh.1151

18. Sallah S, Gonzalez P, Maia DM, Kelekis N, Semelka R. Littoral Cell Angioma in a Patient With Epstein Syndrome. Acta Haematol (1997) 98(2):113–5. doi: 10.11159/a00203601

17. Goldfeld M, Cohen I, Loherant N, Mugrabi A, Katz I, Papura S, et al. Littoral Cell Angioma of the Spleen: Appearance on Sonography and CT. J Clin Imaging (2002) 30(5):310–3. doi: 10.1023/a:1020714656101

16. Johnson C, Goyal M, Kim B, Wasdahl D, Nazinitsky K. Littoral Cell Angioma. Arch Surg (2004) 138(5):429–32. doi: 10.1001/archsurg.2003.46.4.184

15. Johnson J, Björnsson B, Ignatova S, Sandström P, Ekstedt M. Littoral Cell Angioma in a Patient With Crohn’s Disease. Case Rep Gastrointest Med (2015) 2015:474969. doi: 10.1155/2015/474969

14. Nagarajan P, Cai G, Padda MS, Selbst M, Kowalski D, Proctor DD, et al. Littoral Cell Angioma of the Spleen Diagnosed by Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy. Diagn Cytopathol (2011) 39(5):318–

13. doi: 10.1002/path.10101

12. Zhang S, Zhang S, Yan X, Liu G. Relationship Between CT and MR Features and Pathological Features in Littoral Cell Angioma. Chin J Difficult Complicated Cases (2018) 17(12):380–3. doi: 10.3969/j.issn.1671-6450.2018.12.019

11. Ming J, Wang A, Yang Y, Xie G. Splenic Littoral Cell Angioma: A Clinicopathologic Analysis of Two Cases. Pract J Clin Med (2018) 15 (1):217–8. doi: 10.3969/j.issn.1672-6170.2018.01.072

10. Di L, Xu B, Jin X, Zhou H, Shi Q, Zhou X. Splenic Littoral Cell Angioma: A Clinicopathologic Analysis of Three Cases. J Clin Pathol (2010) 17 (2):107–10. doi: 10.3969/j.issn.1000-8096.2010.02.08

9. Fang W, Wang L, Fan Q, Jiang Z, Wu X. Littoral Cell Angioma of Spleen: A Clinicopathologic Analysis of Two Cases. Chin J Pathol (2011) 18 (1):56–8. doi: 10.3969/j.issn.1007-8096.2011.01.016

8. Opatrny V, Treska V, Waloschek T, Molacek J. Littoral Cell Angioma of the Spleen: A Case Report. SAGE Open Med Case Rep (2020) 8:2050313XX0959874. doi: 10.1177/2050313XX0959874

7. Li G, Le M, Gao H. Clinicopathologic Features of Littoral Cell Angioma in Spleen. Chin J Diagn Pathol (2011) 18(2):110–2. doi: 10.3969/j.issn.

6. Johansson B, Björnsson B, Ignatova S, Sandström P, Ekstedt M. Littoral Cell Angioma in a Patient With Crohn’s Disease. Case Rep Gastrointest Med (2015) 2015:474969. doi: 10.1155/2015/474969

5. Li G, Le M, Gao H. Clinicopathologic Features of Littoral Cell Angioma in Spleen. Chin J Diagn Pathol (2011) 18(2):110–2. doi: 10.3969/j.issn.

4. Yan Z, Wu X, Zhan H, Zhang G, Hu S. Laparoscopic Splenectomy for Littoral Cell Angioma of the Spleen: Report of 3 Cases and Review of the
Wang et al. Splenic Littoral Cell Angioma

101. Kinoshita LL, Yee J, Nash SR. Littoral Cell Angioma of the Spleen: Imaging

103. Ramdall RB, Alasio TM, Cai G, Yang GCH. Primary Vascular Neoplasms

100. Ursuleac I, Iosif C, Bădua C, Găman AM, Arsenel D, et al. Littoral Cell Angioma of the Spleen—A Surprising Cause of Anemia. Rom J Morphol Embryol (2013) 54(3 Suppl):885–8.

105. Wang Y-J, Li F, Cao F, Sun J-B, Liu J-F, Wang Y-H. Littoral Cell Angioma of the Spleen. Asian J Surg (2009) 32(3):167–71. doi: 10.1016/S1015-9584(09)

106. Cao F, Wang Y, Li F, Sun J, Liu J, Wang Y. A Case of Splenic Littoral Cell Angioma. Chin J Surg (2008) 46(10):727. doi: 10.3321/j.issn:0529-5815.2008.10.026

107. Li R, Cao M, Xu J, Zhou B, Deng M. A Case of Splenic Littoral Cell Angioma. J Gen Surg (2018) 33(11):974–5. doi: 10.3760/cma.j.issn.1007-631X.2018.11.028

108. Du J, Shen Q, Yin H, Zhou X, Wu B. Littoral Cell Angioma of the Spleen: Report of Three Cases and Literature Review. Int J Clin Exp Pathol (2015) 8(7):8516–20.

109. Borch WR, Aguileras NS, Brissette MD, O’Malley DP, Aubertin A. Practical Applications in Immunohistochemistry: An Immunophenotypic Approach to the Spleen. Arch Pathol Lab Med (2019) 143(9):1093–105. doi: 10.5858/arpa.2018-0211-CP

110. O’Malley DP, Kim YS, Weiss LM. Distinctive Immunohistochemical Staining in Littoral Cell Angioma Using ERG and WT-1. Ann Diagn Pathol (2015) 19(3):143–5. doi: 10.1016/j.anndiagpath.2015.02.007

111. Fadar O, Hileeto D, Mariappan MR. Pathologic Quiz Case: Multiple Splenic Lesions in a Bacteremic Patient. Littoral Cell Angioma of the Spleen. Arch Pathol Lab Med (2004) 128(10):1183–5. doi: 10.1043/1543-2165(2004)128<1183:psmsl>2.0.co;2

112. Yuhai B, Zhiyong S, Xingzhi M, Xiaolu Y, Qiang L, Hui C. Two Cases of Littoral Cell Angioma. Chin J Dig Surg (2008) 7(03):232–4.

113. Lyu S, He Q. Huge Littoral Cell Angioma of the Spleen: A Case Report. J Nippon Med Sch (2019) 86(3):179–82. doi: 10.1272/jnms.NJMS.2019.86-307

114. Fernandez S, Cook GW, Arber DA. Metastasizing Splenic Littoral Cell Hemangioendothelioma. Am J Surg Pathol (2006) 30(8):1036–40. doi: 10.1097/00000478-200608000-00016

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Qi, Zhao, Zhang, Zhu, Liang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.